Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 23;15:10163. doi: 10.1038/s41467-024-54344-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 3 — A–E Tamoxifen was administered daily for 4 consecutive days followed by NP-OVA/alum immunization on day 11. A Expression of GL-7 and Fas in splenic B cells from μMT:Cre^ER (WT), μMT:Cre^ERRraga^fl/flRragb^fl/fl, and μMT:Cre^ERRptor^fl/fl mice. Right, summary of the percentages and numbers of GC B cells. B Expression of CXCR4 and CD86 in GC B cells. Right, summary of the ratio between dark zone (DZ) (CXCR4⁺CD86⁻) and light zone (LZ) (CXCR4⁻CD86⁺) cells. C Expression of CD138 and B220 in spleens. Right, summary of the percentages and numbers of CD138⁺ cells. D ELISA measurement of serum NP₂₃-specific antibodies. WT (n = 7), μMT:Cre^ERRraga^fl/flRragb^fl/fl (n = 8), and μMT:Cre^ERRptor^fl/fl (n = 7). E ELISA measurement of serum NP₂-specific antibodies. WT (n = 5), μMT:Cre^ERRraga^fl/flRragb^fl/fl (n = 5), and μMT:Cre^ERRptor^fl/fl (n = 7). F Expression of p-S6 and p-4EBP1 in fresh or overnight activated splenic B cells. G Heatmap of the mRNA expression of indicated genes in mouse follicular (FO), marginal zone (MZ), and GC B cells. H–L NP-OVA was administered to WT (n = 11), Aicda^CreRraga^fl/flRragb^fl/fl (n = 10), and Aicda^CreRptor^fl/fl (n = 6) mice. H Expression of GL-7 and Fas in splenic B cells. Right, summary of the GC B cell percentages. I Expression of NP and IgG1 in splenic B cells. Right, summary of the percentages of NP⁺IgG1⁺ GC B cells. J Expression of CXCR4 and CD86 on GC B cells. Right, summary of the DZ/LZ ratios. K Expression of CD138 and B220 on splenic lymphocytes. Right, summary of the percentages of CD138⁺ cells. L Expression of CD138 and IgG1 in plasmablasts. Right, summary of the percentages of IgG1⁺ plasmablasts. ELISA measurement of serum anti-NP₂ (M) and anti-NP₂₃ (N) antibodies, WT (n = 13), Aicda^CreRraga^fl/flRragb^fl/fl (n = 8), and Aicda^CreRptor^fl/fl (n = 8). Data in graphs represent mean ± SEM. ns, not significant. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, one-way ANOVA (A–C, F, H, I–L), two-way ANOVA (D, E, M and N). Source data are provided as a Source Data file.